DE3685485D1 - Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung. - Google Patents

Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung.

Info

Publication number
DE3685485D1
DE3685485D1 DE8686309515T DE3685485T DE3685485D1 DE 3685485 D1 DE3685485 D1 DE 3685485D1 DE 8686309515 T DE8686309515 T DE 8686309515T DE 3685485 T DE3685485 T DE 3685485T DE 3685485 D1 DE3685485 D1 DE 3685485D1
Authority
DE
Germany
Prior art keywords
human ovarian
ovarian cancer
mammals
monoclonal antibody
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8686309515T
Other languages
English (en)
Inventor
Michael Jon Bjorn
Arthur Edward Frankel
Walter Joseph Laird
David Barratt Ring
Jeffrey Lee Winkelhake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Application granted granted Critical
Publication of DE3685485D1 publication Critical patent/DE3685485D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE8686309515T 1985-12-06 1986-12-05 Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung. Expired - Fee Related DE3685485D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80625685A 1985-12-06 1985-12-06

Publications (1)

Publication Number Publication Date
DE3685485D1 true DE3685485D1 (de) 1992-07-02

Family

ID=25193669

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686309515T Expired - Fee Related DE3685485D1 (de) 1985-12-06 1986-12-05 Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung.

Country Status (5)

Country Link
EP (1) EP0226418B1 (de)
JP (1) JPS62209098A (de)
AT (1) ATE76583T1 (de)
CA (1) CA1287578C (de)
DE (1) DE3685485D1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806494A (en) * 1986-07-24 1989-02-21 The United States Of America As Represented By The Department Of Health & Human Services Monoclonal antibody against ovarian cancer cells (OVB-3)
US4921790A (en) * 1987-04-24 1990-05-01 Research Corporation Tumor specific assay for CA125 ovarian cancer antigen
WO1989001629A1 (en) * 1987-08-19 1989-02-23 Centocor, Inc. Human ovarian tumor-associated antigen specific for monoclonal antibody ov-tl3
IE62463B1 (en) 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5024834A (en) * 1988-07-12 1991-06-18 Cetus Corporation Thioether linked immunotoxin conjugates
AU6031090A (en) * 1989-07-31 1991-03-11 University Of British Columbia, The Monoclonal antibodies against a tumor-associated antigen
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
US7101977B2 (en) 2001-07-17 2006-09-05 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5843926A (ja) * 1981-09-08 1983-03-14 Suntory Ltd 選択性制癌剤
ATE53496T1 (de) * 1983-03-30 1990-06-15 Lilly Industries Ltd Immunoglobulinkonjugate.

Also Published As

Publication number Publication date
EP0226418A3 (en) 1988-04-27
EP0226418A2 (de) 1987-06-24
CA1287578C (en) 1991-08-13
ATE76583T1 (de) 1992-06-15
JPS62209098A (ja) 1987-09-14
EP0226418B1 (de) 1992-05-27

Similar Documents

Publication Publication Date Title
DE3686313D1 (de) Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung.
Irie et al. Human antibody to OFA-I, a tumor antigen, produced in vitro by Epstein-Barr virus-transformed human B-lymphoid cell lines.
AU605771B2 (en) Monoclanal antibodies to Fc receptors for immunoglobulin G on human mononuclear phagocytes
Nap et al. Specificity and affinity of monoclonal antibodies against carcinoembryonic antigen
Falcioni et al. Monoclonal antibody to human carcinoma-associated protein complex: quantitation in normal and tumor tissue
DE69636015T2 (de) Bispezifische antikörper in denen die bindungsfähigkeit durch eine mittels licht spaltbare gruppe reversibel inhibiert wird
DE69729283D1 (de) GLYKOSYLIERTE IgG ANTIKÖRPER
DK499086A (da) Konjugater af trichothecen og anvendelse af samme som terapeutisk substans
GR1000712B (el) Νεα αντισωματα που αντιδρουν με τα ανθρωπινα καρκινωματα.
MX9701859A (es) Anticuerpos monoclonales en contra de antigenos asociados con carcinoma de colon humano, y usos de los mismos.
WO2003106495A3 (en) MONOCLONAL ANTIBODY HPAM4
EP0265500A4 (de) Antikörper gegen menschlichen progesteronrezeptor sowie diagnosematerial und -verfahren.
KR880700061A (ko) 인체 암종양과 관련된 항원에 대한 단클론성 항체
IL148113A0 (en) Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
ATE71410T1 (de) Tumorspezifische monoklonale antikoerper.
EP0352722A3 (de) Bindungstests für Adenocarcinoma-Antigen und Reagenzien
DE3685485D1 (de) Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung.
LU90955I2 (en) Reopro-fab fragment of chimeric monoclonal antibody 7 e3
SE8800886D0 (sv) Immunoglobulin conjugates
DE59209776D1 (de) Monoklonale Antikörper gegen tumorassoziierte Antigene, Verfahren zu ihrer Herstellung und ihre Verwendung
Nilsson et al. A human lymphoid cell line with an IgG‐like membrane component
EP0380018A3 (en) Rat monoclonal antibodies directed against human antigens and processes for preparation thereof
KR930019820A (ko) 모노클로날 항-강글리오사이드 항체, 이의 제조방법 및 종양 치료제로서의 용도
WO1987007302A3 (en) MONOCLONAL ANTIBODIES TO HUMAN LYMPHOCYTE IgE RECEPTORS, HYBRIDOMAS PRODUCING SUCH ANTIBODIES, AND KITS FOR USING SUCH ANTIBODIES
Nadji et al. Monoclonal antibody ERY-1 identifies an antigen in erythroid cells, hepatocellular and renal cell carcinomas

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CHIRON CORP. (N.D.GES.D. STAATES DELAWARE), EMERYV

8339 Ceased/non-payment of the annual fee